Driehaus Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Driehaus Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,389	Closed	-$56.2K	–	391
2023 Q3	$56.2K	Hold	1,389	–	–	﹤0.01%	390
2023 Q2	$148K	Sell	1,389 -22,909	-94%	-$7.63M	﹤0.01%	377
2023 Q1	$7.25M	Sell	24,298 -7,323	-23%	-$3.13M	0.1%	261
2022 Q4	$10.9M	Buy	+31,621	New	+$7.65M	0.16%	194
2020 Q4	–	Sell	-750	Closed	-$520K	–	422
2020 Q3	$520K	Sell	750 -16,954	-96%	-$12.7M	0.01%	332
2020 Q2	$15M	Sell	17,704 -1,042	-6%	-$680K	0.37%	85
2020 Q1	$6.7M	Buy	+18,746	New	+$6.74M	0.22%	116

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Driehaus Capital Management's BTAI Position: Q4 2023 in Review

Driehaus Capital Management sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 1,389 shares — an estimated $56.2K sold.

Driehaus Capital Management first reported a position in BTAI in Q1 2020 and held it in 7 quarters. The position peaked at $15M in Q2 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

Driehaus Capital Management reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
Driehaus Capital Management sold 1,389 BioXcel Therapeutics shares in Q4 2023, an estimated $56.2K.
Driehaus Capital Management first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 7 quarters.
Driehaus Capital Management's BioXcel Therapeutics position peaked at $15M in Q2 2020.
73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Driehaus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.